152026-07

China Medical System: Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration

CMS Charity | Standing Together with Guangxi: Medical Supplies Worth Over RMB 1 Million Rushed to Disaster Areas

2026-07-13

Recently, affected by Typhoon Maysak combined with sustained heavy rainfall, several regions in Guangxi experienced rising river levels, urban and rural flooding, and other hazards. Transportation and public services were disrupted to varying degrees, and local residents faced mounting pressures on daily life and primary healthcare access. As floodwaters recede and cleanup operations progress, post-disaster health protection efforts have entered a critical phase, including ensuring safe drinking water, environmental disinfection, and preventing intestinal diseases. In this race against the storm, CMS responded swiftly and mobilized resources without delay. Through the Shenzhen Charity Federation, the company donated medical supplies worth over RMB 1 million to the affected areas, including disinfectants and anti-diarrheal medications, to support essential healthcare services and primary-level health protection in the disaster-hit areas. The supplies have been dispatched to the front lines under the Federation’s coordination, expedited to reach those in need and contribute to disaster relief and post-disaster recovery. Safeguarding life and […]

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

2026-06-22

Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus, which is consistent with the WHO recommendation for a “cocktail” therapeutic paradigm; Silevimig Injection provides immediate protection, can be manufactured at scale with standardized processes, and carries no risks of blood-borne infections. Silevimig Injection is the passive immunization product with the smallest dose for rabies, resulting in less injection volume and easier administration, which can effectively reduce patient pain and improve compliance. Silevimig Injection will provide patients with a new option for passive immunization against rabies, and efficiently synergize with the Group’s existing expert network and market resources.   China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the “Product”, trade name: 金速希®), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the […]